13-Mar-2026
Ocugen spikes as Oppenheimer issues new Outperform on upcoming catalysts
Seeking Alpha News (Wed, 11-Mar 11:45 AM ET)
Benzinga (Wed, 11-Mar 7:54 AM ET)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Wed, 4-Mar 8:15 AM ET)
Globe Newswire (Mon, 2-Mar 7:02 AM ET)
Globe Newswire (Wed, 18-Feb 7:02 AM ET)
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
Globe Newswire (Mon, 9-Feb 7:02 AM ET)
Globe Newswire (Fri, 23-Jan 8:00 AM ET)
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Globe Newswire (Wed, 21-Jan 8:32 AM ET)
Globe Newswire (Thu, 15-Jan 8:15 AM ET)
Globe Newswire (Tue, 13-Jan 7:00 AM ET)
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ocugen trades on the NASDAQ stock market under the symbol OCGN.
As of March 13, 2026, OCGN stock price climbed to $2.48 with 14,792,747 million shares trading.
OCGN has a beta of 1.25, meaning it tends to be more sensitive to market movements. OCGN has a correlation of 0.06 to the broad based SPY ETF.
OCGN has a market cap of $811.75 million. This is considered a Small Cap stock.
Last quarter Ocugen reported $-193,000 in Revenue and -$.06 earnings per share. This fell short of revenue expectation by $-1 million and met earnings estimates .
In the last 3 years, OCGN traded as high as $2.67 and as low as $.35.
The top ETF exchange traded funds that OCGN belongs to (by Net Assets): VTI, KOMP, VXF, ITOT, VHT.
OCGN has outperformed the market in the last year with a price return of +357.1% while the SPY ETF gained +21.4%. OCGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +82.4% and +36.3%, respectively, while the SPY returned -2.6% and -3.5%, respectively.
OCGN support price is $2.19 and resistance is $2.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCGN shares will trade within this expected range on the day.
